From Promise to Reality: Advancing Cell Therapies Beyond Oncology

Optimize Safety, Drive Clinical Response and Explore In Vivo, Allogeneic & Autologous Approaches to Spearhead the Next Frontier of Cell Therapy Innovation in Autoimmune Disease

The 4th Cell Therapy for Autoimmune Disease Summit returns to Philadelphia as the only industry-focused meeting uniting developers working across autologous, allogeneic, and in vivo cell therapy approaches for autoimmune disease. Bringing together pioneering biotech, pharma, and academic leaders, the summit will explore the latest advances across lupus, multiple sclerosis, rheumatoid arthritis, and rare autoimmune indications.

The timing has never been more important. Following breakthrough proof-of-concept studies and early clinical successes, 2026 is set to deliver a wave of highly anticipated clinical updates across multiple cell therapy modalities. As developers race toward commercially viable, disease-modifying therapies, the field must now address the challenges of safety, scalability, durability, and patient access.

With dedicated tracks covering Preclinical Development & Translation and Clinical Development, gain practical insights from leaders at Artiva Biotherapeutics, Cabaletta Bio, PolTREG, Orca Bio, Overland Therapeutics, and more as they share the latest innovations shaping the future of immune reset therapies.

Download the Agenda

"The rapid and remarkable expansion of research in the use of cell therapy to treat autoimmune diseases has revealed the great potential for these novel approaches to transform the lives of patients with these challenging diseases."

Peter Merkel, Professor of Medicine Rheumatology, University of Pennsylvania

University of Pennsylvania   - cell therapy autoimmune disease

"Cell therapies for autoimmune diseases have entered a new phase in 2026 with promising clinical data and recent approvals across multiple modalities including T regulatory, CAR-T, and in vivo engineered cell therapies."

Dan Shelly, Chief Business Development Officer, Immuthera / PolTREG

"The conference had a great set of attendees from academia, biotech and large pharma. This facilitated progressive and open discussion during talks, panels and roundtables."

Thomas Furmanak, Director - Translational Medicine, Cabaletta Bio

“The conference was great. I made important contacts and met interesting people. Great information exchange opportunity! Will definitely come again next year!”

Senior Scientist, Clinical Immunology, Cartesian Therapeutics, 2025 Delegate